Akcea Archives -

Less than a week into 2020 and NICE has provisionally ruled against NHS funding for another drug –

Akcea’s rare disease drug Waylivra way too pricey for NHS, says NICE

https://pharmaphorum.com/news-market-access/akceas-rare-disease-drug-waylivra-way-too-pricey-for-nhs-says-nice/

News/ Top stories

Alnylam to file rare kidney disease drug after trial win

Richard Staines Akcea, Alnylam, Rare diseases, RNA interference 0 Comment

After years where RNA interference research was in the doldrums, Alnylam is on a roll and is preparing

Alnylam to file rare kidney disease drug after trial win

https://pharmaphorum.com/news/alnylam-to-file-rare-kidney-disease-drug-after-phase-3-win/

News/ News/ R&D

Pfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drug

Richard Staines Akcea, Diabetes, Ionis, NASH, Pfizer 0 Comment

Pfizer has signed a deal with Ionis’ affiliate Akcea Therapeutics, to develop a potential blockbuster antisense therapy to

Pfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drug

https://pharmaphorum.com/news/pfizer-inks-deal-with-ionis-and-akcea-for-potential-blockbuster-diabetes-and-nash-drug/

Market Access/ News/ News

Ionis’ FCS drug approved in EU, launch due in Germany

Richard Staines Akcea, Ionis Pharmaceuticals, market access, ultra-rare diseases 0 Comment

Ionis Pharmaceuticals’ RNA-targeted drug Waylivra has been conditionally approved in Europe for the devastating ultra-rare disease Familial Chylomicronemia

Ionis’ FCS drug approved in EU, launch due in Germany

https://pharmaphorum.com/news/ionis-fcs-drug-approved-in-eu-launch-due-in-germany/

Market Access/ News/ News

NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay

Phil Taylor Akcea, Alnylam, hATTR, market access, NICE, Rare diseases 0 Comment

NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in

NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay

https://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/

News

Akcea/Ionis’ rare disease drug Waylivra set for EU market after rejection in US

Richard Staines Akcea, familial chylomicronemia syndrome, Ionis, Rare diseases 0 Comment

European regulators have recommended a licence for Akcea and Ionis’ ultra-rare disease drug Waylivra, a therapy that the

Akcea/Ionis’ rare disease drug Waylivra set for EU market after rejection in US

https://pharmaphorum.com/news/akcea-ionis-rare-disease-drug-waylivra-set-for-eu-market-after-rejection-in-us/

News/ News/ R&D

Novartis licenses lipoprotein-lowering CVD drug

George Underwood Akcea, cardiovascular, CVD, Ionis, Novartis 0 Comment

Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment

Novartis licenses lipoprotein-lowering CVD drug

https://pharmaphorum.com/news/novartis-licenses-lipoprotein-lowering-cvd-drug/

News/ News/ R&D

Eyeing Novartis deal, Akcea trumpets lipoprotein drug data

Phil Taylor Akcea, Ionis, lipoprotein, Novartis 0 Comment

Ionis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with

Eyeing Novartis deal, Akcea trumpets lipoprotein drug data

https://pharmaphorum.com/news/eyeing-novartis-deal-akcea-trumpets-lipoprotein-drug-data/

Trending

Akcea

Login